NextCure Inc - ESG Rating & Company Profile powered by AI
The Disclosure rating includes 17 United Nations SDGs including: 'Clean Water & Sanitation', 'Decent Work & Economic Growth' and 'Life on Land'. This report of NextCure Inc is assembled by All Street Sevva using advanced Cognitive Robots. This webpage contains a Q&A table for NextCure Inc.
NextCure Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.6; made up of an environmental score of 2.7, social score of 0.0 and governance score of 8.0.
3.6
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1132 | Taro Pharmaceutical Industries Ltd | 3.7 | Medium |
| 1132 | Traphaco JSC | 3.7 | Medium |
| 1144 | NextCure Inc | 3.6 | Medium |
| 1144 | CellSeed Inc | 3.6 | Medium |
| 1144 | Cellectar Biosciences Inc | 3.6 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does NextCure Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes NextCure Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes NextCure Inc report the average age of the workforce?
Sign up for free to unlockDoes NextCure Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes NextCure Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes NextCure Inc disclose cybersecurity risks?
Sign up for free to unlockDoes NextCure Inc offer flexible work?
Sign up for free to unlockDoes NextCure Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes NextCure Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes NextCure Inc conduct supply chain audits?
Sign up for free to unlockDoes NextCure Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes NextCure Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes NextCure Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes NextCure Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes NextCure Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes NextCure Inc disclose water use targets?
Sign up for free to unlockDoes NextCure Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid NextCure Inc have a product recall in the last two years?
Sign up for free to unlockDoes NextCure Inc disclose incidents of discrimination?
Sign up for free to unlockDoes NextCure Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas NextCure Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes NextCure Inc disclose parental leave metrics?
Sign up for free to unlockDoes NextCure Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes NextCure Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes NextCure Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes NextCure Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes NextCure Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes NextCure Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs NextCure Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes NextCure Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes NextCure Inc disclose its waste policy?
Sign up for free to unlockDoes NextCure Inc report according to TCFD requirements?
Sign up for free to unlockDoes NextCure Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes NextCure Inc disclose energy use targets?
Sign up for free to unlockDoes NextCure Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes NextCure Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for NextCure Inc
These potential risks are based on the size, segment and geographies of the company.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.